Back to today’s briefing

Story perspectives

Proposed Law Aims to Cut U.S. Cancer Drug Prices

5/10/2025

33 4

Summary

Story summary

In the U.S., the cancer drug Revlimid is priced at a staggering $1,000 per pill, far exceeding costs in Europe. With drug companies largely free to set prices, a proposed law seeks to align U.S. prices with those in other affluent nations. However, industry groups are pushing back, fearing increased government intervention in medication pricing.

1 of 1

Story summary

In the U.S., the cancer drug Revlimid is priced at a staggering $1,000 per pill, far exceeding costs in Europe. With drug companies largely free to set prices, a proposed law seeks to align U.S. prices with those in other affluent nations. However, industry groups are pushing back, fearing increased government intervention in medication pricing.